The upgrade in price target by a reputable analyst like Graig Suvannavejh from Mizuho is a strong positive signal for Intra-Cellular Therapies. It suggests a bullish outlook on the stock's future performance, likely due to anticipated operational successes or financial improvements. This can lead to increased investor confidence and potentially drive the stock price up in the short term.